Novadip Biosciences SA, a spinout from the University of Louvain and the Saint-Luc University Hospital, has raised €28 million in a Series A financing round to develop a therapy for bone defects that is based on adipose-derived mesenchymal stem cells.
Faron Pharmaceuticals Oy of Finland has announced its intention to float on the AIM market in London in order to raise money for a Phase 3 trial of its agent for acute respiratory distress syndrome Traumakine, a recombinant human interferon beta-1a.
Netherlands-based Forbion Capital Partners has announced the closing of a new €75 million fund which will enable its existing limited partners to invest in up to six portfolio companies as part of a final financing round before an exit.
The UK-based antiviral drug discovery company ReViral Ltd has raised $21 million in a Series A funding round to support development of a new treatment for infections caused by the respiratory syncytial virus (RSV) that affects infants and older adults.
Laboratoris Sanifit SL, which is developing products for calcification disorders, has raised €36.6 million in a Series C financing from venture capitalists to advance its lead product to protect against the risk of cardiovascular events associated with haemodialysis.
Shield Therapeutics, a UK-based specialty pharmaceutical company, plans to raise up to £110 million in an initial public offering of its shares on the London Stock Exchange to support the development of two late-stage products for the hospital market.
Merus BV of the Netherlands has entered into an agreement with investors to sell up to €72.8 million in Series C preferred shares to support the development of its bispecific antibody therapeutics which are based on the company’s own transgenic mouse technology.
Valeant Pharmaceuticals International Inc has announced plans to acquire Sprout Pharmaceuticals Inc - just two days after Sprout received US regulatory approval to launch a new drug for low sexual desire in premenopausal women.
Kiadis Pharma of the Netherlands has raised an additional €2 million from its initial public offering (IPO) of shares on the Euronext stock exchange in Amsterdam and Brussels following the partial exercise of an over-allotment option.
The Wellcome Trust has awarded $3.84 million to Karuna Pharmaceuticals Inc to further develop a novel treatment for schizophrenia that combines the experimental compound xanomeline with an approved medicine called trospium chloride.